Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
A Randomized Controlled Trial Testing the Efficacy of an Insulin-Dose Learning Algorithm in Adults with Type 1 Diabetes
EF 2019-20
Résumé
"Type 1 diabetes (T1D) is a metabolic disease that results in no insulin production from the pancreas, a hormone required to allow glucose to be used as energy. Despite advances in diabetic treatment technology, maintaining glucose targets is difficult to achieve for most. Therefore, my proposed research will test Dr. Haidar's new personalized learning algorithm (computer-generated decision-making tool) for people with T1D using multiple daily injection (MDI) therapy. This algorithm is designed to estimate optimal insulin doses based on each person's glucose, meal and insulin data over several days. This research is important to Canada because over 300 000 Canadians are currently living with T1D, and the prevalence is expected to rise in the next decade The goal of my master's project is to run a clinical trial to test the efficacy of the algorithm with the fast-growing combined use of MDI therapy and glucose sensor technology (continuously measures glucose levels every five minutes), and examine if the added algorithm will improve glycated hemoglobin (HbA1c) (marker of glucose control over the past three months). This trial will consist of a randomized parallel design, where 84 eligible adults will be recruited at the Research Institute of the McGill University Health Centre, alongside five study endocrinologists, and will randomly undergo one of two interventions at home for three months. The expected outcomes are that the algorithm's recommended adjustments will result in a greater reduction in HbA1c compared to MDI therapy with glucose sensor technology alone. To our knowledge, this data will be the first in Canada to highlight the possibility of incorporating personalized algorithms into smart insulin pens for MDI therapy."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
428886
Name
Kobayati Alessandra
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A Randomized Controlled Trial Testing the Efficacy of an Insulin-Dose Learning Algorithm in Adults with Type 1 Diabetes
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clinical Research; Enhanced Treatment Technology For Type 1 Diabetes; Glucose Control; Glucose Sensor Technology; Insulin Intensive Therapy; Multiple Daily Injections; Personalized Learning Algorithm; Randomized Controlled Trial; Smart Insulin Pens; Type 1 Diabetes
Abstract
"Type 1 diabetes (T1D) is a metabolic disease that results in no insulin production from the pancreas, a hormone required to allow glucose to be used as energy. Despite advances in diabetic treatment technology, maintaining glucose targets is difficult to achieve for most. Therefore, my proposed research will test Dr. Haidar's new personalized learning algorithm (computer-generated decision-making tool) for people with T1D using multiple daily injection (MDI) therapy. This algorithm is designed to estimate optimal insulin doses based on each person's glucose, meal and insulin data over several days. This research is important to Canada because over 300 000 Canadians are currently living with T1D, and the prevalence is expected to rise in the next decade The goal of my master's project is to run a clinical trial to test the efficacy of the algorithm with the fast-growing combined use of MDI therapy and glucose sensor technology (continuously measures glucose levels every five minutes), and examine if the added algorithm will improve glycated hemoglobin (HbA1c) (marker of glucose control over the past three months). This trial will consist of a randomized parallel design, where 84 eligible adults will be recruited at the Research Institute of the McGill University Health Centre, alongside five study endocrinologists, and will randomly undergo one of two interventions at home for three months. The expected outcomes are that the algorithm's recommended adjustments will result in a greater reduction in HbA1c compared to MDI therapy with glucose sensor technology alone. To our knowledge, this data will be the first in Canada to highlight the possibility of incorporating personalized algorithms into smart insulin pens for MDI therapy."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kobayati, Alessandra
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~